Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis

Giuseppe Privitera; Cristina Bezzio; Gisella Figlioli; Ferdinando D’Amico; João Guilherme Tomadon Mendes; Simone Varca; Fabiana Zingone; Iago Rodriguez Lago; S. Onali; Flavio A. Caprioli; María Chaparro; Manuel Barreiro-de Acosta; Konstantinos Karmiris; Natalie Tamir Degabli; Lior Dar; Luca Pastorelli; Ana Gutiérrez; Ambrogio Orlando; Yamile Zabana; Simone Saibeni; Daniele Piovani; Edoardo V. Savarino; Daniela Pugliese; Fernando Magro; Silvio Danese; Alessandro Armuzzi; Serena Valsami; Fabrizio Fanizzi; Paula Ferraz; Franco Scaldaferri; Brigida Barberio; Irene Moraleja; Agnese Favale; Daniele Noviello; Javier P. Gisbert; Porto-Silva Marisol; Andreas Psistakis; Henit Yanai; Uri Kopylov; Mattia Di Pietro; Lucía Madero-Velázquez; Fabio Salvatore Macaluso; Rosalba Orlando; Roberto Gabbiadini; Arianna Dal Buono; Laura S. Loy; Giulia Migliorisi; Caterina Zoratti

doi:10.1016/j.cgh.2026.01.017

January 1, 2026Clinical Gastroenterology and HepatologyOpen Access

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis

View Full Paper

Ask AI

Bookmark

Share

Key Points

To compare the effectiveness of ustekinumab and JAK inhibitors against vedolizumab in ulcerative colitis after anti-TNF failure.
Compared the efficacy of ustekinumab and JAK inhibitors to vedolizumab
Focused on steroid-free and biochemical remission rates
Considered safety profiles for patient selection
Ustekinumab and JAK inhibitors showed higher rates of steroid-free remission than vedolizumab
Biochemical remission rates were also significantly better with ustekinumab and JAK inhibitors
Safety concerns were noted for JAK inhibitors, highlighting the need for careful patient selection

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Ustekinumab and JAK inhibitors improve remission rates in anti-TNF-experienced ulcerative colitis, indicating effective alternatives.

Abstract

Ustekinumab and JAKi were more effective than vedolizumab in inducing steroid-free and biochemical remission following anti-TNFα failure. Safety concerns with JAKi warrant careful patient selection in clinical practice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Privitera et al. (2026) studied this question.

synapsesocial.com/papers/6980fc91c1c9540dea80e65b https://doi.org/10.1016/j.cgh.2026.01.017

View Full Paper

Ask AI

Bookmark

Share

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading